Japan's Otsuka Signs MOU To Invest $83 Million In Korea By 2013
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Japan's Otsuka Pharmaceuticals signed a memorandum of understanding with Korea's health ministry to invest roughly KRW100 billion ($83 million) in research and development of new drugs as well as for clinical trials over the next five years in Korea
You may also be interested in...
Korea Begins To Assess Public Health, Industry Fallout From Japan Disaster
SEOUL - While a growing number of countries such as the U.S., Italy, France, Australia, New Zealand, Britain, China, India and Kyrgyzstan are urging their nationals in Japan to evacuate, South Korea on Thursday started checking radiation levels of people coming into the country from Japan
Korea Begins To Assess Public Health, Industry Fallout From Japan Disaster
SEOUL - While a growing number of countries such as the U.S., Italy, France, Australia, New Zealand, Britain, China, India and Kyrgyzstan are urging their nationals in Japan to evacuate, South Korea on Thursday started checking radiation levels of people coming into the country from Japan
Novartis Signs MOU To Invest $100 Million In R&D, Exchanges With Korean Scientists By 2013
SEOUL - Novartis signed a memorandum of understanding with Korea's Ministry for Health, Welfare and Family Affairs to invest $100 million (KRW 125 billion) over the next five years in the research and development of new drugs, scientific exchanges and collaboration in the life sciences